190 results match your criteria: "Hirakata kohsai Hospital[Affiliation]"
Newly Diagnosed Cancer After Diagnosis of Venous Thromboembolism - Insights From the COMMAND VTE Registry-2.
Circ J
December 2024
Department of Cardiology, Hirakata Kohsai Hospital.
Article Synopsis
- Previous trials suggest no overall benefit of screening for occult cancer in patients with venous thromboembolism (VTE), but high-risk patients may still benefit.
- A study involving 3,706 patients with acute VTE found that the incidence of newly diagnosed cancer increased over time, reaching 3.7% at one year and 7.0% at three years.
- Factors such as older age, a history of cancer, autoimmune disorders, past major bleeding, and lack of transient VTE risk factors were identified as independent predictors for new cancer diagnoses post-VTE.
Low-Gradient Severe Aortic Stenosis: Insights From the CURRENT AS Registry-2.
JACC Cardiovasc Interv
November 2024
Department of Cardiology, Hirakata Kohsai Hospital, Hirakata, Japan. Electronic address:
Background: Low-gradient (LG) aortic stenosis (AS) has not been fully characterized compared with high-gradient (HG) AS in terms of cardiac damage, frailty, aortic valve calcification, and clinical outcomes.
Objectives: The aim of this study was to compare the clinical characteristics and outcomes between each hemodynamic type of LG AS and HG AS.
Methods: The current study included 3,363 patients in the CURRENT AS (Contemporary outcomes after sURgery and medical tREatmeNT in patients with severe Aortic Stenosis) Registry-2 after excluding patients without indexed stroke volume or left ventricular ejection fraction (LVEF) data.
Optimal Intravascular Ultrasound-Guided Percutaneous Coronary Intervention in Patients With Multivessel Disease and Chronic Kidney Disease.
Am J Cardiol
December 2024
Department of Cardiology, Hirakata Kohsai Hospital, Hirakata, Japan. Electronic address:
There is a scarcity of data on clinical outcomes after intravascular ultrasound (IVUS)-guided percutaneous coronary intervention (PCI) in patients with multivessel disease and chronic kidney disease (CKD). The Optimal Intravascular Ultrasound (OPTIVUS)-Complex PCI study multivessel cohort was a prospective multicenter single-arm trial enrolling 1,015 patients who underwent multivessel IVUS-guided PCI including left anterior descending coronary artery target with an intention to meet the prespecified OPTIVUS criteria for optimal stent expansion. We compared the clinical outcomes between patients with and without CKD.
View Article and Find Full Text PDFSafety of Calcium Channel Blockers in Patients With Severe Aortic Stenosis and Hypertension.
Circ J
December 2024
Department of Cardiology, Hirakata Kohsai Hospital.
Background: There is a paucity of data on safety of calcium channel blockers (CCB) in patients with severe aortic stenosis (AS) and hypertension.
Methods And Results: Among 2,460 patients with severe AS and hypertension receiving antihypertensive therapy in the CURRENT AS registry-2, we compared the clinical outcomes between patients taking antihypertensive therapy with CCB (CCB group) and without CCB (no CCB group). In the entire study population, CCB was prescribed in 1,763 patients (71.
Incidence and risk factors of ischemic stroke in patients with cancer-associated venous thromboembolism: from the Contemporary Management and Outcomes in Patients With Venous Thromboembolism Registry-2.
Res Pract Thromb Haemost
November 2024
Department of Cardiology and Nephrology, Mie University Graduate School of Medicine, Tsu, Japan.
Article Synopsis
- * Out of 1507 cancer patients studied, 4.7% experienced an ischemic stroke over a median follow-up of 1020 days, with a cumulative incidence of 4.0% at 1 year.
- * Key risk factors for stroke include specific cancers (pancreatic, ovarian, lung), dyslipidemia, metastasis, elevated D-dimer levels, and younger age, highlighting the need for vigilant monitoring in these patients.
Availability of transcatheter aortic valve implantation across hospitals and differences in strategies and clinical outcomes in patients with severe aortic stenosis.
Cardiovasc Interv Ther
November 2024
Department of Cardiology, Hirakata Kohsai Hospital, 1-2-1 Fujisaka Higashi-Machi, Hirakata, 573-0153, Japan.
Article Synopsis
- * TAVI centers preferred aortic valve replacement (AVR) treatments, with a higher percentage opting for transcatheter aortic valve implantation (TAVI) compared to non-TAVI centers (71% vs. 23%).
- * Despite the differences in treatment frequency, both types of centers showed similar rates of all-cause death or heart failure hospitalizations over three years, indicating no significant outcome difference.
Clinical characteristics and short-term outcomes of patients with critical acute pulmonary embolism requiring extracorporeal membrane oxygenation: from the COMMAND VTE Registry-2.
J Intensive Care
November 2024
Department of Cardiology, Hirakata Kohsai Hospital, 1-2-1, Fujisakashigashimachi, Hirakata-shi, Osaka, 573-0153, Japan.
Article Synopsis
- Extracorporeal membrane oxygenation (ECMO) may be necessary for some patients with severe pulmonary embolism (PE), but its clinical outcomes are not well understood.
- *In a study analyzing data from 2035 patients with acute PE, 76 required ECMO, with findings indicating high rates of cardiac arrest (88.2%) at diagnosis and a 30-day death rate of 30.3%, all related to PE.
- *The research highlighted significant complication rates, including a 54% incidence of major bleeding, suggesting the need for improved management strategies and future clinical trials.
Derivation and Validation of the PRECISE-HBR Score to Predict Bleeding After Percutaneous Coronary Intervention.
Circulation
October 2024
Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland; Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Lugano, Switzerland.
Background: Accurate bleeding risk stratification after percutaneous coronary intervention (PCI) is important for treatment individualization. However, there is still an unmet need for a more precise and standardized identification of high bleeding risk patients. We derived and validated a novel bleeding risk score by augmenting the PRECISE-DAPT score with the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria.
View Article and Find Full Text PDFInitial anticoagulation therapy with single direct oral anticoagulant in patients with intermediate-high risk acute pulmonary embolism: From the COMMAND VTE Registry-2.
Int J Cardiol
January 2025
Department of Cardiology, Hirakata Kohsai Hospital, Hirakata, Japan.
An aspirin-free strategy for percutaneous coronary intervention in patients with diabetes: a pre-specified subgroup analysis of the STOPDAPT-3 trial.
Eur Heart J Cardiovasc Pharmacother
October 2024
Department of Cardiology, Hirakata Kohsai Hospital, Hirakata, Japan.
Aims: Safety of aspirin-free strategy immediately after percutaneous coronary intervention (PCI) for cardiovascular events in patients with diabetes was unknown.
Methods And Results: We conducted the prespecified subgroup analysis on diabetes in the STOPDAPT-3 trial, which randomly compared prasugrel (3.75 mg/day) monotherapy (2984 patients) to dual antiplatelet therapy (DAPT) with prasugrel and aspirin (2982 patients) in patients with acute coronary syndrome or high bleeding risk.
Article Synopsis
- Elevated white blood cell (WBC) counts are identified as a risk factor for adverse outcomes in patients with venous thromboembolism (VTE) who do not have active cancer.
- In a study involving 5,197 patients, those with the highest WBC counts (Q4) were more likely to experience severe forms of VTE like pulmonary embolism and had a significantly higher risk of death and major bleeding over five years.
- The findings suggest that monitoring WBC counts at VTE diagnosis can help in assessing patient risk and potential outcomes.
Article Synopsis
- A study investigated the effects of high-risk coronary artery plaques on late luminal narrowing and clinical events in patients after percutaneous coronary intervention.
- Over one year, the coronary artery lumen area decreased notably, especially in specific types of plaques, such as thin-cap and thick-cap fibroatheromas.
- Thin-cap fibroatheroma presence was linked to a higher risk of needing further revascularization procedures after ischemia, while no significant connection was found between coronary artery calcium levels and clinical outcomes within three years.
Article Synopsis
- * The COMMAND VTE Registry-2 study tracked 5,197 patients with venous thromboembolism in Japan, finding that 2.3% of those with acute PE developed CTEPH over an average follow-up of 747 days.
- * Identified risk factors for developing CTEPH included being female, longer time from symptom onset to PE diagnosis, experiencing hypoxemia, having right heart load, lower D-dimer levels, and having
Left ventricular systolic function after inhalation of beta-2 agonists in healthy athletes.
Sci Rep
October 2024
Division of Sports and Rehabilitation Medicine, Center of Internal Medicine, Ulm University Hospital, Leimgrubenweg 14, 80975, Ulm, Germany.
Inhaled beta-2 adrenoceptor agonists (iβ2A) are routinely used as bronchodilators in the treatment of asthma. However, their cardiac effects in athletes are scarcely examined. Thus, the aim of this study was to evaluate the effects of iβ2A on left ventricular (LV) systolic function (SF) by echocardiography in healthy, non-asthmatic female and male endurance athletes.
View Article and Find Full Text PDFArticle Synopsis
- The simplified Pulmonary Embolism Severity Index (sPESI) score helps identify low-risk patients for home treatment of pulmonary embolism, but its use with direct oral anticoagulants hasn't been thoroughly studied.
- A study of 2,496 patients with stable pulmonary embolism found that only 25% had an sPESI score of 0, and among those, only 17% were treated at home, though their 30-day mortality was notably low (0% vs. 4.8% in higher risk groups).
- Factors promoting home treatment included the absence of temporary risk factors, no elevated cardiac biomarkers, and the use of direct oral anticoagulants during the acute phase.
Importance of non-cardiovascular comorbidities in atrial fibrillation and heart failure with preserved ejection fraction.
ESC Heart Fail
September 2024
Department of Cardiology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Article Synopsis
- Atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) often occur together, but there's limited guidance on managing patients with both conditions, prompting the need for this study.
- The study used data from the Fushimi AF Registry in Japan to identify factors predicting serious outcomes (like cardiac death or HF hospitalization) in AF patients with HFpEF, while also testing these predictors in another patient registry.
- Among 755 patients analyzed, critical risk factors for adverse outcomes included being aged 75 or older and having non-cardiovascular diseases like anemia and diabetes; cardiovascular diseases did not show a significant link to these adverse outcomes.
Impact of Anemia on Clinical Outcomes of Patients With Cancer-Associated Isolated Distal Deep Vein Thrombosis Receiving Edoxaban - Insights From the ONCO DVT Study.
Circ J
September 2024
Department of Cardiovascular and Medicine, Niigata University Graduate School of Medical and Dental Sciences.
Article Synopsis
- * In a subgroup analysis of 601 patients, those with anemia showed significantly fewer recurrent venous thromboembolism (VTE) cases with 12-month edoxaban treatment compared to 3 months, while no such reduction was observed in patients without anemia.
- * Overall, 12-month edoxaban treatment was more effective in preventing thrombotic events for both anemia and no-anemia groups, with no significant difference in major bleeding risk between the two treatment durations.
Utility of the modified Ottawa score for identification of more preferable candidates of extended anticoagulation therapy in cancer-associated isolated distal deep vein thrombosis: insight from the ONCO DVT Study.
J Thromb Haemost
December 2024
Department of Cardiology, Hirakata Kohsai Hospital, Hirakata, Japan.
Article Synopsis
- The ONCO DVT study found that a 12-month course of edoxaban is more effective than a 3-month course for preventing thrombotic events in cancer patients with isolated distal deep vein thrombosis (DVT).
- This analysis categorized 601 patients into three groups based on their modified Ottawa score (low, intermediate, high) to determine the effectiveness of extended anticoagulation.
- Results showed that extended treatment significantly reduced thrombotic events in the intermediate and high score groups but not in the low score group, indicating limited benefit for those with a low risk.
Online Intensive Cardiac Rehabilitation Program for Japanese Patients With Coronary Artery Disease - A Pilot Study Protocol.
Circ Rep
September 2024
Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine Kyoto Japan.
Article Synopsis
- * Twenty-four participants will be split into early and late-phase groups, engaging in a 12-week program that includes exercise, dietary education, mindfulness, and group support sessions.
- * The main goal is to assess the feasibility of the program through adherence, while secondary outcomes will evaluate changes in physical health, stress management, and dietary habits among participants.
Aspirin vs. clopidogrel monotherapy after percutaneous coronary intervention: 1-year follow-up of the STOPDAPT-3 trial.
Eur Heart J
December 2024
Division of Cardiology, Hirakata Kohsai Hospital, 1-2-1, Fujisaka-higashi-machi, Hirakata, Osaka 573-0153, Japan.
Article Synopsis
- A trial, STOPDAPT-3, was conducted to compare aspirin monotherapy and clopidogrel monotherapy after short-term dual antiplatelet therapy in patients who underwent percutaneous coronary intervention using drug-eluting stents.
- The study involved 5,833 patients who were followed for 30 days, focusing on cardiovascular events (like heart attacks) and bleeding complications as primary endpoints.
- Results showed that aspirin and clopidogrel monotherapy had similar rates of cardiovascular and bleeding events up to one year after the intervention, indicating both treatments are equally effective in these contexts.
Article Synopsis
- The study explores the impact of persistent low-grade inflammation on patients with chronic coronary syndrome (CCS), focusing on those treated with higher intensity pitavastatin in the REAL-CAD study.
- It analyzes data from 10,460 patients, looking specifically at their hs-CRP levels at baseline and after 6 months to determine the relationship with cardiovascular events.
- The results indicate that patients with persistently high hs-CRP levels face a significantly increased risk of severe cardiovascular issues compared to those with persistently low levels, highlighting the importance of managing inflammation in CCS patients.
Article Synopsis
- Proton pump inhibitors (PPIs) were studied for their effects on upper gastrointestinal bleeding (UGIB) in patients who underwent percutaneous coronary intervention (PCI), with findings from a large patient registry of 24,563 participants.
- Over a median follow-up of 5.6 years, PPIs significantly reduced the risk of UGIB but showed no impact on myocardial infarction or ischemic strokes, regardless of high-risk patient subgroups.
- Although PPIs helped lower UGIB risk, they were also linked to higher mortality rates, suggesting a complex benefit-risk profile in these patients.
Efficacy and safety of Saireito (TJ-114) in patients with atrial fibrillation undergoing catheter ablation procedures: A randomized pilot study.
PLoS One
August 2024
Department of Cardiovascular Medicine, Hirakata Kohsai Hospital, Kyoto, Japan.
Article Synopsis
- Atrial fibrillation (AF) ablation often leads to early arrhythmia recurrences due to inflammation, prompting the study of Saireito as a potential treatment to reduce these occurrences.
- A randomized trial with 100 patients compared the effects of a 30-day Saireito treatment against a control group, focusing on the frequency of atrial tachyarrhythmias post-ablation.
- Results showed that while the Saireito group had fewer episodes of arrhythmias in the first two weeks, they also experienced more adverse symptoms compared to the control group.
Article Synopsis
- A study in Japan compared outcomes of patients with venous thromboembolism (VTE) treated with warfarin (2010-2014) versus direct oral anticoagulants (DOACs) (2015-2020) from two multicenter registries.
- The use of DOACs skyrocketed from 2.6% in the warfarin era to 79% in the DOAC era, leading to a significant reduction in the 5-year recurrence rate of VTE (10.5% to 9.5%).
- However, the incidence of major bleeding remained similar between the two eras, indicating that while DOACs may reduce VTE recurrence, concerns about bleeding risks continue.
Article Synopsis
- - The study analyzed the impact of using an aspirin-free strategy versus dual antiplatelet therapy (DAPT) in patients undergoing coronary intervention while on oral anticoagulation (OAC).
- - Among nearly 6,000 patients, the outcomes showed no significant difference in major bleeding events between the two strategies, regardless of OAC use.
- - However, there was a slightly higher risk of cardiovascular events with the aspirin-free approach in patients taking OAC, suggesting potential concerns about this strategy's safety in high-risk groups.